Compare GVH & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | BNGO |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 12.9M |
| IPO Year | 2023 | 2018 |
| Metric | GVH | BNGO |
|---|---|---|
| Price | $4.75 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $80.00 | $7.00 |
| AVG Volume (30 Days) | ★ 643.2K | 138.7K |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000,735.00 |
| Revenue This Year | $102,768.97 | $14.99 |
| Revenue Next Year | N/A | $34.73 |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.03 | $1.06 |
| 52 Week High | $10.74 | $5.50 |
| Indicator | GVH | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 43.84 |
| Support Level | $4.34 | $1.13 |
| Resistance Level | $4.90 | $1.18 |
| Average True Range (ATR) | 0.61 | 0.04 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 52.34 | 30.43 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.